Why is Parmax Pharma falling/rising?

As of 07-Jul, Parmax Pharma Ltd's stock is currently priced at 38.50, reflecting a decrease of 0.25, or 0.65%. The stock has been underperforming recently, having fallen consecutively for the last two days, resulting in a total decline of 3.75%. In the past week, the stock has decreased by 2.28%, while it has shown a modest gain of 0.63% over the last month. Despite generating a strong return of 24.64% over the past year, the company faces challenges such as a negative book value and weak long-term growth, with net sales growing at an annual rate of only 6.15%. Additionally, the company's ability to service its debt is concerning, as indicated by a poor EBIT to interest ratio of 0.66, which contributes to its classification as a risky investment.
In the broader market context, the stock's recent performance contrasts with the benchmark, as the Sensex has only declined by 0.20% over the past week. While Parmax Pharma's short-term performance has been negative, the benchmark has shown relative stability. The stock's liquidity appears adequate, with a significant increase in delivery volume, suggesting rising investor participation. However, the overall weak long-term fundamentals and negative operating profits indicate that investors may be cautious, leading to the stock's current downward trend despite its past strong performance.